Clinician's Corner

Clinician's can use the new international guidelines for schizophrenia treatment to solidify treatment decisions and improve patient outcomes.

An FDA committee recently decided the clozapine REMS protocol was no longer necessary. How will this impact clinicians?

The authors of the Clinician's Corner column discuss the latest FDA-approved treatment for schizophrenia.

The context and timing of symptoms is critical for a timely and accurate bipolar diagnosis.

Diagnostic clarity between anhedonia and persistent depressive disorder is paramount in clinical practice to ensure effective and safe treatment for patients.